Axsome Therapeutics Inc
AXSM
Market Cap$3.39B
Close$
$62.31
16.8% downside
Current Fair Value
16.8% downsideOvervalued by 16.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.39 Billion |
|---|---|
| Enterprise Value | $3.18 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.27 |
| Beta | 0.0 |
| Outstanding Shares | 47,374,375 |
| Avg 30 Day Volume | 566,361 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -14.16 |
|---|---|
| PEG | -23.18 |
| Price to Sales | 14.98 |
| Price to Book Ratio | 18.72 |
| Enterprise Value to Revenue | 11.76 |
| Enterprise Value to EBIT | -17.39 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.94 |
Revenue Sources
No data
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...